Digital Day Two

Jam packed with unpublished clinical data, group discussion forums, and new updates in solid tumors and infectious disease, join with your team so you don’t miss a thing!

Showcasing updates from Genentech, Century Therapeutics, Artiva Biotherapeutics and Kuur Therapeutics, join day 2 to get up to speed on …

  • Clinical development of human placental hematopoietic stem cell derived NK cells for the treatment of COVID-19
  • Unpublished clinical data shared from Acepodia and Jeffrey Miller, University of Minnesota focused on off-the-shelf strategies to increase activity and specificity
  • The role of CAR-NKT cells as a solution to the solid tumor challenge
  • Combination approaches with monoclonal antibodies to support the efficacy and potency of NK cell therapy

And much more!

Key speakers include:

Jason Litten


Artiva Biotherapeutics

Jeffrey Miller


University of Minnesota

Mark Lowdell


Inmune Bio

Mark Wallet

VP, Head of Immunology

Century Therapeutics

9:30 - 5:15 EDT | 6:30 - 12:15 PDT

9:00 am Coffee & Networking

9:25 am Chair’s Opening Remarks

Keynote Clinical Data

9:30 am Allogeneic Off-the-Shelf NK Cell Therapy Using Antibody Cell Conjugation (ACC)


• Introduction of Acepodia’s oNK and ACC platforms
• Preclinical studies of anti-HER2 conjugated oNK cells (ACE1702)
• Clinical trials of ACE1702 in the US

Unpublished Data

9:55 am NK Cell Therapeutics: Off-the-shelf Strategies to Increase Activity and Specificity


• Understand the differentiation of NK cells from induced pluripotent stem cells (iNK)
• Review the early clinical safety and activity of iNK
• Outline the clinical power of immune engagement with IL-15 containing TriKEs

Unpublished Data

10:20 am Allogeneic Natural Killer Cell Therapy for Patients with Relapsed/Refractory Lymphoid Malignancies: Novel Strategy Using Nicotinamide Ex Vivo Expansion


• Review novel therapeutic product using allogeneic NK cells expanded with nicotinamide and IL-15 ex vivo (GDA-201), which is characterized by potent cytotoxicity,  cytokine production, resistance to oxidative stress and enhanced ability to persist in vivo and traffic to tumor sites.

• In the first in human Phase 1 study in patients with relapsed/refractory non-Hodgkin lymphoma and multiple myeloma we examined GDA-201 Maximum Tolerated Dose and safety profile with no evidence of immune mediated adverse events

• Discuss the demonstration of substantial clinical efficacy and durable remissions in patients with follicular lymphoma and DLBCL with novel correlative data

Unpublished Data

10:45 am Tech Slam


Quickfire 10-minute presentations from the leading solution providers in the space.

11:15 am Refreshment Break

1:30 pm Speaker Break Out Discussions


Our speakers of the previous session will join the speaker break out room where you can meet them, ask any further questions you might have and continue the conversation

1:45 pm Refreshment Break

2:45 pm Round Table Discussion Session


1. NK Therapy for Infectious Disease
• Review the possibility of treating viral infections with NK-cell therapy
• Discuss the clinical need and market opportunity
• Identify which viral infections should be targeted
• Review the NK-cell engineering strategies that are needed to target viral infections
Elie Haddad, Head, Research Axis, Immune Disorders & Cancers, CHU Sainte-Justine

2. Enhance Clinical Efficacy Through Combination Approaches
• Discuss the possibility of combining current NK cell-based immunotherapies with monoclonal antibodies, different types of engagers, small molecules, and/or established drugs which may offer additional impact of NK cells in therapeutic settings
• Outline the pros and cons, challenges and opportunities, lessons learned and experiences to date
Hans-Gustaf Ljunggren, Professor, Group Leader, Karolinska Institute

3. What are the Requirements for Successful Natural Killer Cell Therapy? Studies from Cancer patients and Those in Humanized Mice
• Discuss different NK cell therapeutics in the market and compare and contrast the advantages and disadvantages of each platform
• Delineate the requirements for successful NK cell therapy
• Consider the ability to kill tumor cells at different stages of differentiation and their ability to successfully target tumor cells without becoming inactivated by the tumor
• Review combined therapies with NK cell therapy such as chemotherapy, radiation, oncolytic virus therapy, CAR-T and CAR-NK therapy and CD8+ T cell therapy
Anahid Jewett, Professor & Director, Tumor Immunology Laboratory, UCLA

Understanding NK Cell Interaction in the TME to Tackle Solid Tumors

3:30 pm Exploring the Network of Cellular Interactions of NK Cells in the Tumor Microenvironment


• Describe NK cell : tumor cell : NK cell interactions and the definition of “NK resistance”
• Review regulatory T cells and regulatory NK cells in the TME
• Potentiation of impaired NK function in the TME to overcome hypoxia-induced suppression

3:55 pm CAR-NKT Cells: A Solution to the Solid Tumor Challenge


• Examine the biology of NKT cells
• Share approaches to engineer NKT cells to attack solid tumors
• Describe preclinical and early clinical proof of concept

The Role of NK in Viral Infection

4:20 pm Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19


• Celularity has developed a novel proprietary GMP procedure that enables the scalable production of an off-the-shelf, allogeneic NK cell therapy (CYNK-001)
• Combining pathogenic mechanism of coronavirus, existing and validated research results, we hypothesize adoptive CYNK001 therapy may provide the antiviral activities thereby serve as effective solutions for COVID-19 patients
• Discuss the initial findings from our clinical investigation and continuous development of CYNK-001 for infectious diseases

4:45 pm NK Cell Immunotherapy as a HIV Cure Strategy and in the Context of Non-Aids-Defining Cancer Treatments


• Human NK cells mediate adaptive immune responses to virally encoded antigens, including HIV-Env, in humanized mice and human volunteers
• NK cells lower HIV viral titers in CTL depleted HIV-challenged humanized mice
• NK cell adoptive transfers into syngeneic HIV-naive humanize mice lower HIV viral titers upon experimentally HIV challenged

5:10 pm Chair’s Closing Remarks

5:15 pm Close of Summit